兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06622 兆科眼科-B

已收盘 06-15 15:59:29

2.830

-0.030

-1.05%

最高2.860	最低2.760	成交量69.70万
今开2.860	昨收2.860	日振幅3.50%
总市值15.54亿	流通市值15.54亿	总股本5.49亿
成交额196.72万	换手率0.13%	流通股本5.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06622","market":"HK","secType":"STK","nameCN":"兆科眼科-B","latestPrice":2.83,"timestamp":1781510369323,"preClose":2.86,"halted":0,"volume":697000,"delay":0,"changeRate":-0.010489510489510422,"floatShares":549000000,"shares":549000000,"eps":-0.382096,"marketStatus":"已收盘","change":-0.03,"latestTime":"06-15 15:59:29","open":2.86,"high":2.86,"low":2.76,"amount":1967245,"amplitude":0.034965,"askPrice":2.84,"askSize":5000,"bidPrice":2.77,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-0.4252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781573400000},"marketStatusCode":5,"adr":0,"listingDate":1619625600000,"exchange":"SEHK","adjPreClose":2.86,"openAndCloseTimeList":[[1781487000000,1781496000000],[1781499600000,1781510400000]],"volumeRatio":0.660538,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06622/wiki","defaultTab":"wiki","newsList":[{"id":"2643222896","title":"兆科眼科-B：减慢儿童近视滴眼液澳洲注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2643222896","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643222896?lang=zh_cn&edition=full","pubTime":"2026-06-15 12:49","pubTimestamp":1781498940,"startTime":"0","endTime":"0","summary":"6月15日，兆科眼科-B（06622）发布公告，澳洲TherapeuticGoodsAdministration（治疗用品管理局）已受理评估公司就其用于减慢儿童近视加深疗法的硫酸阿托品滴眼液提出的注册申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606153771340145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","BK1583","06622","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171753296","title":"兆科眼科-B硫酸阿托品滴眼液申请获澳大利亚TGA受理评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1171753296","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171753296?lang=zh_cn&edition=full","pubTime":"2026-06-15 12:10","pubTimestamp":1781496646,"startTime":"0","endTime":"0","summary":"兆科眼科-B旗下硫酸阿托品滴眼液的新药申请，已正式获澳大利亚药品管理局（TGA）受理并进入评估阶段。此举标志着该产品在澳大利亚监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06622","BK1191","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122699125","title":"兆科眼科-B回购17.4万股股份，耗资约47.32万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122699125","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122699125?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:17","pubTimestamp":1781176638,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司（“兆科眼科-B”，06622）于2026年6月11日发布公告称，公司当日于香港联交所场内回购普通股17.4万股，约占该日公司现有已发行股本的0.0317%。本次回购股份最高及最低每股价格分别为2.72港元及2.699港元，涉资总额约47.32万港元。\n公告显示，截至本次变动结束后，公司已发行股本仍为548,749,012股，库藏股数量保持为0股。根据公告，兆科眼科有限公司已于2026年5月15日通过购回授权，最高可购回股份数量为54,874,901股。\n公司在公告中确认，已遵守港交所相关上市规则及相关法律规定。公告由董事李小羿签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B回购17.4万股股份，耗资约47.32万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289535","title":"兆科眼科-B(06622)6月11日斥资47.32万港元回购17.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289535","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642289535?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:16","pubTimestamp":1781176603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)发布公告，于2026年6月11日斥资47.32万港元回购17.4万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06622","BK1583","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157885686","title":"兆科眼科-B批准高达1亿港元股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1157885686","media":"投资观察","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157885686?lang=zh_cn&edition=full","pubTime":"2026-06-08 23:45","pubTimestamp":1780933537,"startTime":"0","endTime":"0","summary":"兆科眼科-B有限公司（6622.HK）宣布，其董事会已批准一项为期十二个月的股份回购计划，授权公司动用最高达1亿港元的资金，在公开市场上回购其股份。\n根据该计划，公司获准回购的股份数量最高可达已发行股份总数的10%，即约5487万股。\n此次股份回购计划旨在优化公司的资本结构，提升每股收益，并可能向市场传递管理层对公司未来前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1587","BK1191","06622","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641920481","title":"兆科眼科-B(06622)拟回购最多1亿港元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641920481","media":"智通财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641920481?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:01","pubTimestamp":1780920065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)公布，董事会已批准一项为期12个月的股份购回计划，总购回金额不超过1亿港元。根据购回授权，公司获准购回最多达于授出购回授权的相关决议案通过当日已发行股份总数10%(即54,874,901股股份)的本身股份。根据购回授权购回的股份将于适当时候注销。公司在制定股份购回计划时已考虑多项因素，包括其业务前景、经营表现、财务状况及未来盈利能力。董事会认为，实行股份购回计划展现其对集团业务前景及展望的信心，并将有助于为股东创造长远价值。公司计划使用其内部资源为股份购回提供资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1587","BK1574","06622","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100113","title":"【券商聚焦】国海证券：李氏大药厂(00950)战略收购催化价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100113","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100113?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:10","pubTimestamp":1780909801,"startTime":"0","endTime":"0","summary":"关键催化事件：2025年12月，公司全资附属子公司NPI以1500万美元收购Alexza核心资产，获得Staccato One Breath Technology吸入给药技术平台及相关产品管线、知识产权和生产设施。公司连同NPI有望就Staccato阿普唑仑获得最高6050万美元的里程碑付款+分级特许权使用费。Staccato阿普唑仑用于癫痫发作的3期临床预计2026年读出主要终点。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983252","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1587","BK1191","BK0188","06622","BK0174","BK0276","BK0028","BK1583","000750","BK1574","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126529962","title":"兆科眼科与PT. Erela就环孢素眼用凝胶在印尼市场达成经销协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1126529962","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126529962?lang=zh_cn&edition=full","pubTime":"2026-06-05 12:16","pubTimestamp":1780632977,"startTime":"0","endTime":"0","summary":"兆科眼科-B宣布，已与印度尼西亚公司PT. Erela就其核心产品环孢素眼用凝胶在印尼市场达成经销协议。此举标志着该公司在拓展东南亚市场方面迈出了关键一步。\n根据协议，PT. Erela将获得该产品在印尼的独家经销权，负责其市场推广、销售及分销。环孢素眼用凝胶主要用于治疗干眼症，该市场在印尼乃至整个亚太地区均呈现出显著的增长潜力。\n此次合作旨在利用PT. Erela在当地的成熟渠道与市场专业知识，加速产品准入并扩大市场份额。对兆科眼科而言，这不仅为其产品组合开辟了新的增长空间，也强化了其国际化商业布局的战略实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1191","BK1574","BK1583","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640909331","title":"董事总经理李烨妮增持李氏大药厂(00950)4.15万股 每股作价1.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640909331","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640909331?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:08","pubTimestamp":1780484900,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月29日，董事总经理李烨妮增持李氏大药厂(00950)4.15万股，每股作价1.06港元，总金额约为4.4万港元。增持后最新持股数目约为1.28亿股，最新持股比例为21.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","EWH","BK1583","BK1191","BK1574","BK1587","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957411","title":"李氏大药厂(00950)：合成表面活化剂项目获批资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957411","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640957411?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:07","pubTimestamp":1780322823,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，李氏大药厂将获得盖茨基金会的财务资金，以支持集团的合成表面活化剂项目。此获资助项目的短期目标为成功完成研究及开发活性药物成分(API)及制剂，以及该药物的制造过程。最终目标为以可负担的价格将此款救命药物引进中低收入国家，特别是为帮助患上呼吸窘迫症候群的早产婴儿。董事会认为，盖茨基金会提供的资金支持相当切合公司在儿科及罕见病领域的策略重点，彰显集团对提高全球获得医疗保健服务的机会的持续承诺，并运用其创新的药物递送平台满足关键的医疗需求缺口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00950","BK1587","BK1574","BK1583","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197814961","title":"兆科眼科-B5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1197814961","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197814961?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:52","pubTimestamp":1780296736,"startTime":"0","endTime":"0","summary":"兆科眼科-B于2026年6月1日公布截至2026年5月31日的证券变动月报。报告期内，公司法定/注册股本维持1,600,000,000,000股普通股，面值每股0.00000025美元，总额400,000美元，与上月一致。已发行股份数量继续保持在548,749,012股，未出现增发、购回或注销情况，公司库存股份数量为0股，报告期内无变化。报告显示各计划涉及股份期权数目与上期持平，报告期内未发生明显增减。公告最后显示，公司确认已遵守香港联交所上市规则及相关法律规定，并由董事李小羿签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634280989","title":"李氏大药厂(00950)拟斥资2500万元参投生命健康产业基金 布局生物科技赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2634280989","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634280989?lang=zh_cn&edition=full","pubTime":"2026-05-11 22:26","pubTimestamp":1778509575,"startTime":"0","endTime":"0","summary":"李氏大药厂(00950)公布，于2026年5月11日，公司的间接全资附属公司兆科合肥、普通合伙人瑞伏博健及其他有限合伙人订立有限合伙协议，据此，该等合伙人向基金出资人民币2亿元，而兆科合肥同意向基金出资人民币2500万元，相当于约12.5%基金权益。基金的目的为寻求投资于生命与健康、生物科技及相关上下游行业的非上市实体，符合公司的业务策略，透过于医药领域的策略合伙、投资及收购加强业务。投资基金符合集团的核心策略，透过具影响力的合伙及收购扩大其医药及保健版图。借认购基金的有限合伙权益，该集团得以间接涉足生物科技及生命科学领域的非上市实体的高增长，善用普通合伙人深厚的行业知识。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1587","HBImain","BK1574","BK1191","06622","BK4588","XBI","00950","159837","BK1583","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144884208","title":"兆科眼科-B 4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1144884208","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144884208?lang=zh_cn&edition=full","pubTime":"2026-05-05 12:51","pubTimestamp":1777956667,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年5月5日发布截至2026年4月30日的股份变动月报表。根据公告，公司截至本月末的股本结构与上月底相比保持不变。于4月30日，公司已发行的普通股数量维持在548,749,012股，库藏股数量为0股，均与上月底一致。兆科眼科-B在公告中同时声明，所有涉及本月股份及期权的相关事项均按上市规则及法律法规办理，已获董事会正式审批。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115075463","title":"兆科眼科-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1115075463","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115075463?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:36","pubTimestamp":1776937000,"startTime":"0","endTime":"0","summary":"兆科眼科-B宣布，董事会已获授权可于股东周年大会通过后，于决议生效期间内回购不超过该公司已发行股本总数的10%。截至最后实际可行日期，兆科眼科-B共发行约5.49亿股，此次授权最高可回购约5487万股。据悉，股东周年大会定于2026年5月15日举行，股份过户将于2026年5月12日至5月15日暂停办理。董事会表示，如有需要且符合公司及股东利益，未来将在大会授权范围内酌情实施股份购回。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177942711","title":"兆科眼科-B（06622）2025年亏损收窄至2.09亿元 核心管线多点开花","url":"https://stock-news.laohu8.com/highlight/detail?id=1177942711","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177942711?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:00","pubTimestamp":1776934812,"startTime":"0","endTime":"0","summary":"兆科眼科-B于2025年度在研发与商业化领域取得多项进展，财务表现方面虽仍录得亏损，但亏损幅度较上年有所收窄。公司聚焦眼科领域创新药物和已有产品的市场拓展，并持续完善全球布局与内部治理结构。由于收入规模减少及其他收入的收窄，公司经营亏损约2.00亿元人民币，年内亏损2.09亿元人民币，同比收窄12.01%。综上所述，兆科眼科-B在2025年于主要研发管线和全球化运营上均有显著进展，同时亏损规模有所收窄。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B（06622）2025年亏损收窄至2.09亿元 核心管线多点开花","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146829215","title":"兆科眼科-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1146829215","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146829215?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:45","pubTimestamp":1775033145,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年4月1日发布2026年3月股份变动月报表，报告期截至3月31日。根据公告，公司的注册股本维持在400,000美元，报告期末已发行股份总数保持为548,749,012股，未发生新的股份发行或购回注销情况，整体股本结构未见变动。上述期权变动并未造成任何新增股份的发行，亦无库存股份减持或转让。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623318798","title":"李氏大药厂(00950)发布年度业绩 股东应占溢利9193.8万港元 同比减少1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623318798","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623318798?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:19","pubTimestamp":1774862354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布截至2025年12月31日止年度业绩，集团收益14.36亿港元，同比增长2.6%;股东应占溢利9193.8万港元，同比减少1.2%;每股盈利15.61港仙;拟派末期股息每股2.3港仙。公告称，公司拥有人应占纯利减少反映严峻市场环境及研发支出增加的合并影响，抵销了收益增长及销售费用减少所带来的裨益，导致纯利同比下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1587","BK1191","06622","BK1574","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071591","title":"李氏大药厂(00950)：茵若飒取得国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071591","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622071591?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:37","pubTimestamp":1774445826,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，于2026年3月17日，中国国家药品监督管理局(国家药监局)已批准茵若飒(由Cosette Pharmaceuticals拥有并已授予李氏大药厂许可)用于治疗具有中重度症状(不包括泌尿系症状)的绝经后女性外阴阴道萎缩。继本公司全资附属公司兆科药业(合肥)有限公司进行的第III期、多中心、随机、双盲、平行对照临床试验成功完成后，是次获批标志着一个重要的里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06622","BK1191","BK1587","BK1583","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145677103","title":"兆科眼科-B 2025年收入回落，持续推进多款眼科创新药布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1145677103","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145677103?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:50","pubTimestamp":1774439401,"startTime":"0","endTime":"0","summary":"兆科眼科-B于截至2025年12月31日的报告期内录得收入人民币31,974千元，较上一年度的人民币69,324千元出现下滑，主要由于部分药物及产品销售收益减少，以及一次性许可收入较上年度有所降低。毛利从2024年度的人民币51,797千元下降至人民币16,053千元。报告期末，兆科眼科-B的资产总值约为人民币1,935,312千元，负债总额约为人民币359,425千元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622078438","title":"兆科眼科-B(06622)公布2025年业绩 税后亏损约2.09亿元 同比收窄12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078438","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622078438?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:46","pubTimestamp":1774439191,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)公布2025年业绩，收益3197.4万元，同比减少53.88%;税后亏损约2.09亿元，同比收窄12%。公告称，亏损减少主要源于集团继续严格控制行政费用及销售及分销开支，反映年内成本控制有所加强及营运架构效率提升。此外，研发开支随着若干主要开发里程碑达成而有所减少，并无如上一年度产生非经常性开支亦进一步推动改善。尽管并无如上一年度取得一次性的许可收入，且2025年利率下调令银行利息收入减少，惟集团取得的年内亏损仍然实质收窄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1574","BK1191","BK1583","06622"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1216},{"period":"1month","weight":0.0214},{"period":"3month","weight":-0.1254},{"period":"6month","weight":-0.0804},{"period":"1year","weight":-0.1063},{"period":"ytd","weight":-0.0338}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"兆科眼科有限公司是一家主要从事眼科药物及产品的开发、生产及营销的投资控股公司。该公司的主要产品包括用于治疗近视的NVK002（阿托品）、用于治疗干眼症的环孢素A眼凝胶以及用于治疗wAMD的TAB014（贝伐单抗）。该公司产品主要用于干眼症（DED）、近视、老花眼、湿性老年黄斑部病变（wAMD）和糖尿病黄斑水肿（DME）、青光眼及角膜上皮细胞功能障碍（CED）等影响眼前节及眼后节的眼科疾病的治疗。该公司在中国国内及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.147188},{"month":2,"riseRate":0.2,"avgChangeRate":-0.134185},{"month":3,"riseRate":0.2,"avgChangeRate":-0.040318},{"month":4,"riseRate":0.2,"avgChangeRate":0.019445},{"month":5,"riseRate":0.333333,"avgChangeRate":0.015956},{"month":6,"riseRate":0.333333,"avgChangeRate":0.05655},{"month":7,"riseRate":0.4,"avgChangeRate":-0.054975},{"month":8,"riseRate":0.2,"avgChangeRate":-0.017626},{"month":9,"riseRate":0.6,"avgChangeRate":0.007418},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082811},{"month":11,"riseRate":0.4,"avgChangeRate":0.029799},{"month":12,"riseRate":0.2,"avgChangeRate":-0.018114}],"exchange":"SEHK","name":"兆科眼科-B","nameEN":"ZHAOKE OPHTH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兆科眼科-B,06622,兆科眼科-B股票,兆科眼科-B股票老虎,兆科眼科-B股票老虎国际,兆科眼科-B行情,兆科眼科-B股票行情,兆科眼科-B股价,兆科眼科-B股市,兆科眼科-B股票价格,兆科眼科-B股票交易,兆科眼科-B股票购买,兆科眼科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}